Allergy Shot Risks: Exact Per-Injection Probabilities, Explained
Every allergy shot carries a calculable per-injection risk: local reactions in 26-86% of patients, large local reactions in 0.4-5.3% of injections, any systemic reaction in roughly 1 in 500-1,000 injections, Grade 3 severe reactions at 1 per 300,000 visits, Grade 4 anaphylaxis at 1 per 160,000 visits, and fatal reactions at 1 per 9 million visits. Build-up and cluster protocols carry higher rates than maintenance.
7 peer-reviewed sources
Per injection, allergy shots carry a local reaction risk of 26-86%, systemic reaction risk of 0.1-0.2%, and fatal anaphylaxis risk of roughly 1 per 9 million injection visits — with build-up and cluster protocols at the higher end.
What Is the Exact Risk Per Allergy Shot Injection?
If you want numbers rather than reassurance, this is the right page. Every injection in a course of allergy shots carries a specific per-injection probability of producing a particular outcome. The probability pyramid ranges from very likely (local redness) through very unlikely (fatal anaphylaxis), with each tier having a real denominator from peer-reviewed surveillance data.
The primary data source is the AAAAI/ACAAI National Surveillance Study series, the largest ongoing safety surveillance program for allergen immunotherapy. The series covers over 54.4 million injection visits from 2008 to 2016 (Epstein 2019, JACI Pract) and provides per-injection rates for outcomes at every level of severity. The WAO systemic reaction grading paper (Cox 2010, JACI) provides the classification framework.
Before beginning any course of allergy shots, knowing exactly which allergens are in your extract matters enormously — because the per-injection risk depends partly on how sensitive you are to those specific allergens. Comprehensive allergy testing through Curex, covering 40+ allergens from home, gives your allergist the IgE data needed to calibrate your starting dose and build-up schedule appropriately.
This page presents per-injection risk across all outcome levels, the temporal risk curve (when during treatment are reactions most likely), and how specific protocol factors shift the per-injection probability.
Per-injection risk is real but quantifiable. Local reactions are common and expected. Severe and fatal reactions are rare but not hypothetical. Understanding the full probability pyramid is what separates informed consent from uncertainty.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youPer-Dose Risk: At-Home SCIT Injections vs Sublingual Immunotherapy
The most direct per-dose comparison between SCIT and SLIT shows a meaningful difference in systemic risk at every tier. Both modalities achieve the same underlying immune tolerance outcome through different routes with different risk profiles. The per-injection risk of SCIT is real but quantifiable and manageable — which is exactly why at-home SCIT through Curex pairs each dose with a prescribed epinephrine auto-injector on hand and Zoom-supervised first and changed doses for eligible maintenance patients. The comparison below frames the tradeoff for patients weighing the two routes.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
At-Home SCIT Shots (Curex) — RECOMMENDEDBest | 33-85% symptom reduction; covers virtually all aeroallergens | 3-5 years; 150-200 total injections | $3,000-10,000 with insurance | Weekly clinic visits; 30-minute post-injection observation required | Systemic rate: 0.1-0.2% per injection; Grade 4: 1 per 160K; Fatal: 1 per 9M |
Sublingual Drops/Tablets (SLIT) | Comparable efficacy for covered allergens; same immune-tolerance mechanism | 3-5 years; daily home dosing | Varies by allergen and program | Daily home dose after supervised first dose | Systemic rate: ~0.056% per dose; severe: ~2% of those; no confirmed fatalities worldwide |
No Immunotherapy (Pharmacotherapy Only) | Symptom suppression only; allergies not modified; may worsen over time | Indefinite daily medication | $1,000-4,000 for medications | No clinic visits required for injections | No per-injection risk; medication-specific risks only |
- Efficacy
- 33-85% symptom reduction; covers virtually all aeroallergens
- Duration
- 3-5 years; 150-200 total injections
- Cost (5yr)
- $3,000-10,000 with insurance
- Convenience
- Weekly clinic visits; 30-minute post-injection observation required
- Safety
- Systemic rate: 0.1-0.2% per injection; Grade 4: 1 per 160K; Fatal: 1 per 9M
- Efficacy
- Comparable efficacy for covered allergens; same immune-tolerance mechanism
- Duration
- 3-5 years; daily home dosing
- Cost (5yr)
- Varies by allergen and program
- Convenience
- Daily home dose after supervised first dose
- Safety
- Systemic rate: ~0.056% per dose; severe: ~2% of those; no confirmed fatalities worldwide
- Efficacy
- Symptom suppression only; allergies not modified; may worsen over time
- Duration
- Indefinite daily medication
- Cost (5yr)
- $1,000-4,000 for medications
- Convenience
- No clinic visits required for injections
- Safety
- No per-injection risk; medication-specific risks only
For patients who find the per-injection risk concerning, the answer is not necessarily a different treatment — it is the same immunotherapy with the right safeguards. Curex offers at-home SCIT at $129/month: a board-certified allergist confirms candidacy (screening out high-risk subgroups), the first injection and every dose change are supervised live over Zoom, a prescribed epinephrine auto-injector is confirmed on hand before the first dose, and the personalized serum is sterile-compounded to USP <797> standards. Patients with risk factors that make home administration unsafe are identified during candidacy review and referred to in-person care.
See if at-home shots are right for youThe Per-Injection Risk Probability Pyramid
Each tier of this probability pyramid represents a different level of adverse outcome following an allergy shot injection. The probabilities are per-injection (or per-visit) rates based on published surveillance data, not per-patient lifetime rates. A patient who receives 180 injections over a 4-year course accumulates 180 independent per-injection risk events — so per-injection and per-course risk calculations are presented separately where available. Data sources: Bernstein 2010 (Ann Allergy; Year 1 surveillance, 8.1M visits); Epstein 2019 (JACI Pract; 54.4M visits); LOCAL Study (Calabria 2009, JACI); Roy 2007 (Ann Allergy); Cox 2010 WAO grading paper.
When to Worry: Decision Guide
Are your symptoms confined to the injection site only — no symptoms elsewhere in your body?
Local reaction — not a systemic event
Ice, antihistamine if desired. Report LLR (swelling over quarter-size) to allergist before your next injection. No emergency action required.
Systemic involvement — use epinephrine and call 911 now
Act on your emergency action plan immediately — in a clinic, alert staff; with at-home SCIT, contact your Curex care team and follow your written reaction protocol. Per-injection systemic rate is ~0.1-0.2% — you are in that fraction; the clinical response is standard.
Do you have difficulty breathing, throat tightness, or feel faint?
Possible Grade 3-4 — emergency response required
Epinephrine IM immediately. Call 911. Per the probability pyramid, you are in the less-than-1-per-160,000 tier — this is the emergency that the 30-minute wait is designed to catch.
Grade 1-2 systemic reaction — urgent but manageable
Stay put for full evaluation — in a clinic, remain on site; at home, do not drive and stay reachable for your Curex allergist. Follow treatment per your allergist protocol, with extended observation until symptoms fully resolve.
Frequently asked questions
What is my cumulative risk over a full course of allergy shots?
A standard 3-5 year course of allergy shots involves approximately 150-200 total injections — about 40-60 during build-up (weekly) plus 120-140 during maintenance (monthly over 3-4 years). At the per-injection systemic reaction rate of 0.1-0.2%, the expected probability of experiencing at least one systemic reaction over a full course is approximately 15-40% per patient, depending on which rate applies to their protocol. Grade 1-2 reactions account for 97% of systemic reactions, so most of these expected events would be mild to moderate. The probability of experiencing a Grade 3 severe reaction over 150 injections works out to approximately 1 in 2,000 patients completing a full course, and Grade 4 anaphylaxis to approximately 1 in 1,000 patients — real numbers that reflect cumulative, not per-injection, exposure.
Is the risk higher at the beginning or end of allergy shot treatment?
The per-injection risk profile differs between treatment phases in a counterintuitive way. During build-up (the first 3-6 months), each injection escalates the dose, so mild and moderate systemic reaction rates are higher per injection than in maintenance. However, fatal and severe reactions have paradoxically shown higher representation during maintenance phase in historical surveillance. The explanation lies in new vial transitions: maintenance patients return monthly and are more likely to receive the first injection from a fresh vial, when potency variation can produce a more biologically active dose than the patient's immune system has been conditioned to. The Bernstein 2004 fatality survey found that 59% of documented fatalities occurred during maintenance phase. Both phases require the 30-minute observation and epinephrine availability — the risk does not simply decrease once maintenance is reached.
How does a cluster allergy shot schedule affect per-injection risk?
Cluster build-up schedules — which give 2-4 injections per visit rather than one, reaching maintenance in 4-8 weeks instead of 3-6 months — carry approximately three times the per-injection systemic reaction rate of conventional build-up. A Johns Hopkins study (Tversky 2022, JACI; n=91) found a per-injection systemic reaction rate of 0.69% for standard build-up versus 2.29% for cluster, an incidence rate ratio of 3.3 (95% CI 1.5-7.3). A multicenter cluster cohort (Ann Allergy, 2011; n=441) reported a 10.9% per-patient systemic reaction rate during cluster build-up — 38% Grade 1, 49% Grade 2, 11% Grade 3, 2% Grade 4. These elevated rates reflect the more rapid dose escalation. Cluster protocols typically require antihistamine premedication, 30-minute monitoring between same-day injections, and peak flow checks before each dose.
Does the per-injection risk go up during allergy season?
Yes, the per-injection risk of moderate and severe systemic reactions is meaningfully elevated during a patient's primary pollen season. The biological mechanism is mast cell priming: repeated mucosal exposure to airborne allergen during peak season upregulates tissue mast cells and eosinophils, increasing the inflammatory response to the same maintenance injection dose. The Epstein 2013 Year 3 surveillance study demonstrated the clinical consequence: practices that always reduced doses during peak season had significantly fewer Grade 2-3 reactions (44% vs. 65%, P=0.04). Standard practice is to reduce the maintenance dose by 50% during a patient's peak season and return to maintenance afterward. Patients should expect this dose reduction as a safety protocol rather than a setback, and should inform the clinic if pollen counts are particularly high on injection days.
What shifts my per-injection risk up or down?
Several factors can meaningfully shift your individual per-injection risk above or below the population baseline rate. Risk increases with: uncontrolled asthma on the day of injection (the single largest risk modifier — associated with 88% of fatalities); a cluster or rush build-up schedule (approximately 3x per-injection rate); new vial transition without dose reduction; injection during peak pollen season without seasonal dose adjustment; beta-blocker use (impairs epinephrine rescue response); and prior systemic reaction history (4x higher recurrence per Roy 2007). Risk decreases with: controlled, well-optimized asthma; conventional build-up at a conservative pace; pre-injection asthma assessment before each shot; dose reduction at new vial transitions; and peak-season dose reduction. A patient with no risk factors on a conventional protocol is meaningfully below the average rate; a patient with multiple risk factors on a cluster protocol may be significantly above it.
How does the per-injection risk of allergy shots compare to sublingual immunotherapy?
The per-dose systemic reaction rate for SCIT is approximately 0.1-0.2% per injection (Bernstein 2010; Epstein 2019). For sublingual immunotherapy, the WAO 2014 Position Paper reports a rate of 0.056% of doses across 314,959 analyzed doses (Canonica, World Allergy Organ J 2014). On a per-dose basis, this represents a roughly 2-3 fold lower systemic reaction rate for SLIT. The difference in severity distribution is more pronounced: approximately 19% of SCIT systemic reactions were classified as severe, compared to approximately 2% of SLIT systemic reactions in an indirect comparison study (Dretzke 2013, JACI). Most critically, no fatal reaction has ever been confirmed from sublingual immunotherapy worldwide, while SCIT carries a documented per-injection fatal reaction rate of approximately 1 per 9 million visits. Both are low-risk in absolute terms, but the safety profiles differ meaningfully at the severe-outcome tier.
Is there any way to reduce my per-injection risk before each allergy shot visit?
Several practical steps can reduce your per-injection risk before each visit. Check your breathing before each appointment: if you are wheezing, breathless, or your asthma feels worse than usual, call your allergist before going in — a deferred injection is safer than proceeding with uncontrolled asthma. Avoid vigorous exercise in the two hours before and after your injection, as physical exertion may lower the anaphylaxis threshold. Inform the clinic of any illness, respiratory infection, or unusual symptom on the day of your appointment. During peak pollen season, expect and confirm with your clinic that a dose reduction is in place. At new vial transitions, confirm that the 50% dose reduction protocol is being followed. Never skip the 30-minute observation period — even when feeling well after previous injections. If you take beta-blockers, ensure your allergist has a documented plan for glucagon availability as an alternate rescue agent.
Related Articles
Side Effects of Allergy Shots: WAO Classification | Curex
Side effects of allergy shots ranked by WAO severity grade — local reactions, Grade 1-4 systemic events, rates per injection, and what each tier means.
Read moreAllergy Shot Reaction When to Worry | SCIT Guide | Curex
Allergy shot reaction when to worry: local wheals are normal. Hives, throat tightness, or dizziness outside the injection arm means seek immediate care.
Read moreWhat Is Allergy Shots? Quick Definition and How It Works
What is allergy shots? SCIT trains your immune system to tolerate allergens over 3-5 years. 85-90% of patients see significant improvement.
Read moreAllergy Shot Side Effects: Per-Injection Timeline | Curex
What happens after each allergy shot? A minute-by-minute timeline from the 30-min wait to 48-hour local reactions, with safety thresholds and real data.
Read moreAllergy Immunotherapy Guide: All Options Compared | Curex
Allergy immunotherapy covers shots, tablets, drops, and OIT. Compare SCIT vs SLIT on efficacy, safety, cost, and FDA status to choose the right route.
Read moreAllergy Shots: Complete SCIT Guide for Patients | Curex
Allergy shots (SCIT) reduce symptoms by 33-85% over 3-5 years. Learn how they work, what they cost, and who qualifies for this disease-modifying treatment.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.